Endocrine Abstracts

Introduction: Use of degludec [tresiba] in children and adolescents with type 1 diabetes was approved by EC 2015 and FDA in December 2016. Degludec is a new ultra-long acting basal insulin with terminal half-life of approximately 25 hours and duration of action of more than 42 hours. Constant release of insulin throughout the day leads to better control of blood glucose for more than 24 hours with significant reduction in HbA1c.Aim: To compare and assess...